Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Argus Health
Cerilliant
Accenture
Medtronic
Fuji
US Army
Novartis
Covington
Harvard Business School
Fish and Richardson

Generated: October 18, 2017

DrugPatentWatch Database Preview

Details for Patent: 9,101,543

« Back to Dashboard

Which drugs does patent 9,101,543 protect, and when does it expire?


Patent 9,101,543 protects ABRAXANE and is included in one NDA. There has been one Paragraph IV challenge on Abraxane.

This patent has seventy-three patent family members in twenty-five countries.

Summary for Patent: 9,101,543

Title:Combinations and modes of administration of therapeutic agents and combination therapy
Abstract: The present invention provides combination therapy methods of treating proliferative diseases (such as cancer) comprising a first therapy comprising administering to an individual an effective amount of a taxane in a nanoparticle composition, and a second therapy which may include, for example, radiation, surgery, administration of chemotherapeutic agents, or combinations thereof. Also provided are methods of administering to an individual a drug taxane in a nanoparticle composition based on a metronomic dosing regime.
Inventor(s): Desai; Neil P. (Los Angeles, CA), Soon-Shiong; Patrick (Los Angeles, CA)
Assignee: ABRAXIS BIOSCIENCE, LLC (Los Angeles, CA)
Application Number:13/585,696
Patent Claim Types:
see list of patent claims
Use; Composition;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Abraxis Bioscience
ABRAXANE
paclitaxel
FOR SUSPENSION;IV (INFUSION)021660-001Jan 7, 2005RXYesYes► Subscribe► Subscribe TREATMENT OF PANCREATIC CANCER
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Patent: 9,101,543

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,268,348Combinations and modes of administration of therapeutic agents and combination therapy► Subscribe
7,758,891Combinations and modes of administration of therapeutic agents and combination therapy► Subscribe
8,034,375Combinations and modes of administration of therapeutic agents and combination therapy► Subscribe
8,257,733Methods and compositions for treating proliferative diseases► Subscribe
8,735,394Combinations and modes of administration of therapeutic agents and combination therapy► Subscribe
7,780,984Methods and compositions for treating proliferative diseases► Subscribe
9,561,288Combinations and modes of administration of therapeutic agents and combination therapy► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 9,101,543

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria531365► Subscribe
Australia2006213999► Subscribe
Australia2007317859► Subscribe
BrazilPI0607809► Subscribe
BrazilPI0718528► Subscribe
Canada2598239► Subscribe
Canada2668607► Subscribe
Canada2902071► Subscribe
China101160123► Subscribe
China101573108► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Fuji
Baxter
Chubb
UBS
Federal Trade Commission
Daiichi Sankyo
Cantor Fitzgerald
Farmers Insurance
QuintilesIMS
Citi

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot